BioRestorative Therapies (OTC: BRTX) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. The company’s two core programs relate to the treatment of disc/spine disease and metabolic disorders. The company’s disc/spine program, or brtxDISC™, encompasses its lead cell therapy candidate BRTX-100 which has received clearance from the FDA to commence a phase 2 clinical trial to treat chronic lower back pain due to degenerative disc disease related to protruding or bulging discs. The company’s metabolic program, or ThermoStem® program, is developing a cell-based therapy to target obesity and metabolic disorders using fat derived stem cells to generate brown adipose tissue. For more information, visit the company’s website at www.biorestorative.com
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides to users (1) access to our news aggregation and syndication servers, (2) enhanced press release services, and (3) a full array of social communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
[email protected]
